News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN) Announces First European Commission Approval of Injectable Treatment Using NanoCrystal(R) Technology



3/10/2011 10:30:06 AM

DUBLIN--(BUSINESS WIRE)--Elan Drug Technologies (EDT), the drug delivery unit of Elan Corporation, plc (NYSE: ELN), today announced that the first injectable product using EDT’s NanoCrystal® technology has been approved by the European Commission. XEPLION®, Janssen-Cilag International NV’s long-acting injectable treatment for patients with schizophrenia which uses EDT’s NanoCrystal® technology, was approved by the European Commission earlier today.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES